VCU Massey Cancer Center researcher Swadesh K. Das, Ph.D., was recently selected as a senior member of the National Academy of Inventors. The National Academy of Inventors (NAI) is a nonprofit organization that enhances the visibility of academic technology and innovation as a means to ultimately benefit humanity. The NAI senior member program, which is distinct from the NAI Fellows Program, was launched in 2018 to “identify and recognize early stage innovators and inventors whose patents have the potential to bring real impact on society.”
Born and raised in rural North Carolina, VCU doctoral candidate Bonny Morris, MSPH, RN, knows first-hand the challenges that patients in rural communities face in accessing cancer care.
Morris, who is currently pursuing a doctoral degree in social and behavioral sciences at the Department of Health Behavior and Policy at the VCU School of Medicine, conducts research at VCU Massey Cancer Center that investigates the factors that contribute to cancer treatment disparities in rural communities. Through a rigorous mixed method design supported by community engagement, she aims to develop targeted, tailored approaches that improve outcomes for underserved cancer patient populations.
Massey researchers first to show that a specific protein inhibitor successfully kills multiple myeloma tumor cells
Cyclin-dependent kinase inhibitor 7 (CDK7) is a protein that regulates cell cycle progression. However, it also plays a key role in controlling transcription of three genes that help tumor cells proliferate and survive in patients with multiple myeloma, a form of plasma cell cancer.
VCU Massey Cancer Center partners with Children’s Hospital of Richmond at VCU to offer CAR T-cell therapy to children
This summer, VCU Massey Cancer Center in partnership with Children’s Hospital of Richmond at VCU (CHoR) became a certified treatment center for Novartis’ KYMRIAH, an FDA-approved CAR T-cell therapy for acute lymphoblastic leukemia in children and young adults. Massey was the first in Virginia to offer an FDA-approved CAR T-cell therapy last year with Gilead’s YESCARTA, and the addition of KYMRIAH is another milestone in providing expanded access to cutting-edge cellular immunotherapies.
Virginia Commonwealth University Massey Cancer Center researchers Guizhi (Julian) Zhu, Ph.D., and Yue Sun, Ph.D., are two of just 18 researchers at VCU to receive awards from the Presidential Research Quest Fund.